Business Context and Reporting Period
This Form 8-K is a current report filed by Obalon Therapeutics, Inc. (not Vyome Holdings, Inc.) on March 15, 2017, regarding events occurring on March 13, 2017. The filing discloses corporate governance changes involving the appointment of a new director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Annual Cash Retainers: $35,000 for Board service, $7,500 for the Audit Committee, and $5,000 for the Compensation Committee.
- Stock Option Grant: 59,988 shares at an exercise price of $9.55 per share.
Material Changes
The material change reported is the appointment of David Moatazedi as a Class II Director, effective March 13, 2017. He was simultaneously appointed to the Audit Committee and the Compensation Committee. No material changes to financial operations or business strategy are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of risks and contingencies. It confirms that there are no undisclosed arrangements regarding Mr. Moatazedi's appointment and that he holds no material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the correct registrant name is Obalon Therapeutics, Inc., not Vyome Holdings, Inc.
- Confirm the vesting schedule of the 59,988 stock options granted to the new director (monthly over three years).
- Review the standard indemnification agreement referenced as Exhibit 10.1 to the Form S-1 filed on September 26, 2016.
- Note that this filing does not contain financial results; refer to the most recent 10-K or 10-Q for financial metrics.